Dr Reddy’s launches Carboprost Tromethamine injection in US

Our Bureau Hyderabad | Updated on July 03, 2019 Published on July 03, 2019

Dr. Reddys Laboratories.   -  The Hindu

Pharma major Dr Reddy’s Laboratories Ltd has launched Carboprost Tromethamine Injection, a therapeutic equivalent generic version of Hemabate injection approved by the US Food and Drug Administration (USFDA).

“We are pleased to be first-to-market with this product that has been designated as a Competitive Generic Therapy (CGT) by the FDA,” Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy’s Laboratories said in a release issued here on Wednesday. “With a CGT designation, we have 180-day CGT exclusivity to market this product,’’ he added.

The Hemabate injection brand had US sales of approximately $55 million for the most recent twelve months ending in April 2019 according to IQVIA Health. Hemabate is a trademark of Pfizer.

At 2.40 pm, the stocks of Dr Reddy’s were trading 1.07 per cent lower at ₹2,600.

Published on July 03, 2019
This article is closed for comments.
Please Email the Editor